Drug General Information
Drug ID	D08IDC
Former ID	DNC008618
Drug Name	3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[529624]
Structure		Download 2D MOL 3D MOL
Formula	C17H15NO2
Canonical SMILES	COC1=CC2=C(C=C1)C=C(C=C2)C3=CC(=CN=C3)OC
InChI	1S/C17H15NO2/c1-19-16-6-5-12-7-13(3-4-14(12)8-16)15-9-17(20-2)11-18-10-15/h3-11H,1-2H3
InChIKey	SEXSHORPOJSDHK-UHFFFAOYSA-N
PubChem Compound ID	24827305
Target and Pathway
Target(s)	Cytochrome P450 11B1, mitochondrial	Target Info	Inhibitor	[529624]
	Cytochrome P450 3A4	Target Info	Inhibitor	[529624]
BioCyc Pathway	Superpathway of steroid hormone biosynthesis
	Glucocorticoid biosynthesis
	Mineralocorticoid biosynthesis
KEGG Pathway	Steroid hormone biosynthesis
	Metabolic pathwayshsa00140:Steroid hormone biosynthesis
	Linoleic acid metabolism
	Retinol metabolism
	Metabolism of xenobiotics by cytochrome P450
	Drug metabolism - cytochrome P450
	Drug metabolism - other enzymes
	Metabolic pathways
	Bile secretion
	Chemical carcinogenesis
PathWhiz Pathway	SteroidogenesisPW000015:Caffeine Metabolism
	Retinol Metabolism
Reactome	Glucocorticoid biosynthesis
	Endogenous sterolsR-HSA-211981:Xenobiotics
	Aflatoxin activation and detoxification
WikiPathways	Metapathway biotransformation
	Oxidation by Cytochrome P450
	Metabolism of steroid hormones and vitamin D
	Corticotropin-releasing hormoneWP702:Metapathway biotransformation
	Aflatoxin B1 metabolism
	Estrogen metabolism
	Benzo(a)pyrene metabolism
	Tamoxifen metabolism
	Tryptophan metabolism
	Nuclear Receptors in Lipid Metabolism and Toxicity
	Nuclear Receptors Meta-Pathway
	Farnesoid X Receptor Pathway
	Vitamin D Receptor Pathway
	Felbamate Metabolism
	Lidocaine metabolism
	Nifedipine Activity
	Colchicine Metabolic Pathway
	Irinotecan Pathway
	Drug Induction of Bile Acid Pathway
	Fatty Acid Omega Oxidation
	Codeine and Morphine Metabolism
References
Ref 529624	J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.
Ref 529624	J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.